ATE225666T1 - Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung - Google Patents

Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung

Info

Publication number
ATE225666T1
ATE225666T1 AT95901918T AT95901918T ATE225666T1 AT E225666 T1 ATE225666 T1 AT E225666T1 AT 95901918 T AT95901918 T AT 95901918T AT 95901918 T AT95901918 T AT 95901918T AT E225666 T1 ATE225666 T1 AT E225666T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
acute
producing
kidney disease
Prior art date
Application number
AT95901918T
Other languages
English (en)
Inventor
Howard R Higley
Christopher A Maack
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE225666T1 publication Critical patent/ATE225666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT95901918T 1993-11-15 1994-11-15 Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung ATE225666T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15286293A 1993-11-15 1993-11-15
PCT/US1994/013178 WO1995013824A1 (en) 1993-11-15 1994-11-15 Method of treating renal disease by administering igf-i and igfbp-3

Publications (1)

Publication Number Publication Date
ATE225666T1 true ATE225666T1 (de) 2002-10-15

Family

ID=22544774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901918T ATE225666T1 (de) 1993-11-15 1994-11-15 Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung

Country Status (8)

Country Link
US (1) US5723441A (de)
EP (1) EP0732933B1 (de)
JP (1) JPH09509141A (de)
AT (1) ATE225666T1 (de)
AU (1) AU690941B2 (de)
CA (1) CA2176709A1 (de)
DE (1) DE69431527T2 (de)
WO (1) WO1995013824A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
CA2289123A1 (en) * 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
PT1384075E (pt) * 2001-03-28 2010-03-23 Heska Corp Métodos de detecção de doença renal inicial em animais
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20040152170A1 (en) * 2001-12-14 2004-08-05 Lee Chichang Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
US20030166147A1 (en) * 2001-12-14 2003-09-04 Lee Chichang Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
WO2003052064A2 (en) * 2001-12-14 2003-06-26 Centocor Inc. Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
US20050272649A1 (en) * 2002-08-28 2005-12-08 Hruska Keith A Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20100028302A1 (en) * 2004-09-27 2010-02-04 Ludwig-Maximilians- Universität München Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
EP1817058B1 (de) * 2004-11-24 2015-09-02 Hill's Pet Nutrition, Inc. Zusammensetzung zur verwendung der verbesserung der beseitigung von xenobiotischen substanzen aus der leber bei einem tier
WO2006069029A1 (en) * 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2006236345B2 (en) * 2005-04-19 2011-03-31 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
AU2006242463A1 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
CA2608670C (en) * 2005-05-20 2019-03-05 Hill's Pet Nutrition, Inc. Methods for promoting health or wellness in adult animals
EP1896070A4 (de) * 2005-06-29 2009-04-29 Hills Pet Nutrition Inc Verfahren und zusammensetzungen für die vorbeugung und behandlung von nierenerkrankungen
CN101287460B (zh) 2005-08-17 2012-04-25 希尔氏宠物营养品公司 预防和治疗肾病的组合物
EP1952823A1 (de) * 2007-01-30 2008-08-06 AM-Pharma B.V. Verwendung von alkalischer Phosphatase bei der Behandlung eingeschränkter Nierenfunktion
ES2810813T3 (es) 2014-01-24 2021-03-09 Am Pharma Bv Procesamiento para recuperación y purificación de una fosfatasa alcalina
CA2937328C (en) 2014-01-24 2022-09-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
EP0327503B1 (de) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure

Also Published As

Publication number Publication date
DE69431527D1 (de) 2002-11-14
EP0732933B1 (de) 2002-10-09
EP0732933A1 (de) 1996-09-25
DE69431527T2 (de) 2003-06-26
JPH09509141A (ja) 1997-09-16
CA2176709A1 (en) 1995-05-26
EP0732933A4 (de) 1996-11-06
AU1098295A (en) 1995-06-06
US5723441A (en) 1998-03-03
WO1995013824A1 (en) 1995-05-26
AU690941B2 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
DE69431527D1 (de) Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
Meunie Spatial organization and mineralization of the basal plate of elasmoid scales in osteichthyans
Tonna et al. Autoradiographic studies of cell proliferation in the periosteum of intact and fractured femora of mice utilizing DNA labeling with H3-thymidine.
Hirasawa et al. Blood purification for prevention and treatment of multiple organ failure
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
DE69332624D1 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
DE69033903D1 (de) Verwendung von Sertraline zur Herstellung eines Arzneimittels zur Behandlung von obsessiv-kompulsiven Erkrankungen
TR200001248T2 (tr) Anti-CD40L bileşikleri ile lupus nefritis tedavisi
EA200000058A1 (ru) Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
DE69504646D1 (de) Herstellung und stabilisierung von zellsuspensionen
DE60012517D1 (de) Methoden zur behandlung von diabetes
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE59610205D1 (de) Anwendung eines medikaments und verwendung eines stoffgemischs zur herstellung eines medikaments
DE10055703A1 (de) Verhinderung der Zellzerstörung und Beseitigung sklrotischer Amyloide verursacht durch organspezifische Antikörperaggregate
Grogan et al. Pseudotumor cerebri with amiodarone
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
SU1664325A1 (ru) Способ лечени гнездного облысени
DE69222636D1 (de) Anti-hiv protein, tap-29, aus trichosanthes, seine kodierende dna und therapeutischen anwendungen
Dober Epileptische Psychosen ohne epileptische Anfälle und ihre Differentialdiagnostik
DE1617566C (de) Verfahren zur Herstellung eines physio logisch aktiven Polypeptide
Woggon et al. Open trial and double-blind clinical trial of the antidepressant Ro 8-1998 in comparison with imipramine
MAEDA et al. Usefulness of Hachimi-jio-gan and other Kampo Drugs for Gonarthrosis
SU1445728A1 (ru) Способ лечени гипертонической болезни

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties